Multivariate analysis of the prognostic value of OPAL1 expression in pediatric ALL
. | COALL . | . | . | . | St Jude . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable . | N . | HR . | 95% CI . | P . | N . | HR . | 95% CI . | P . | ||||||
| Age | ||||||||||||||
| No older than 10 y | 131 | 1.0* | NA | 181 | 1.0* | NA | ||||||||
| Older than 10 y | 49 | 1.24 | 0.64-2.41 | .52 | 76 | 1.37 | 0.67-2.79 | .39 | ||||||
| WBC count | ||||||||||||||
| Less than 10 × 109/L | 43 | 1.0* | NA | 90 | 1.0* | NA | ||||||||
| 10 × 109-49 × 109/L | 67 | 0.54 | 0.19-1.49 | .23 | 80 | 0.99 | 0.42-2.34 | .99 | ||||||
| 50 × 109-100 × 109/L | 28 | 1.03 | 0.35-3.02 | .95 | 40 | 0.78 | 0.24-2.46 | .68 | ||||||
| More than 100 × 109/L | 42 | 1.59 | 0.58-4.32 | .36 | 47 | 1.32 | 0.52-3.34 | .56 | ||||||
| ALL subtype | ||||||||||||||
| B-other | 53 | 1.0* | NA | 82 | 1.0* | NA | ||||||||
| BCR-ABL | 4 | 2.32 | 0.51-10.6 | .28 | 9 | 9.09 | 2.48-33.3 | < .001 | ||||||
| Hyperdiploid† | 40 | 0.15 | 0.03-0.65 | .01 | 50 | 0.84 | 0.28-2.45 | .74 | ||||||
| MLL rearranged | 4 | 9.51 | 2.47-36.5 | .001 | 8 | 1.97 | 0.37-10.3 | .42 | ||||||
| TEL-AML1 | 44 | 0.18 | 0.05-0.68 | .01 | 70 | 0.93 | 0.18-4.73 | .93 | ||||||
| T-lineage | 35 | 0.79 | 0.33-1.93 | .6 | 38 | 2.73 | 1.11-6.71 | .029 | ||||||
| OPAL1 expression | 180 | 1.03 | 0.77-1.34 | .9 | 257 | 0.71 | 0.4-1.28 | .25 | ||||||
. | COALL . | . | . | . | St Jude . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable . | N . | HR . | 95% CI . | P . | N . | HR . | 95% CI . | P . | ||||||
| Age | ||||||||||||||
| No older than 10 y | 131 | 1.0* | NA | 181 | 1.0* | NA | ||||||||
| Older than 10 y | 49 | 1.24 | 0.64-2.41 | .52 | 76 | 1.37 | 0.67-2.79 | .39 | ||||||
| WBC count | ||||||||||||||
| Less than 10 × 109/L | 43 | 1.0* | NA | 90 | 1.0* | NA | ||||||||
| 10 × 109-49 × 109/L | 67 | 0.54 | 0.19-1.49 | .23 | 80 | 0.99 | 0.42-2.34 | .99 | ||||||
| 50 × 109-100 × 109/L | 28 | 1.03 | 0.35-3.02 | .95 | 40 | 0.78 | 0.24-2.46 | .68 | ||||||
| More than 100 × 109/L | 42 | 1.59 | 0.58-4.32 | .36 | 47 | 1.32 | 0.52-3.34 | .56 | ||||||
| ALL subtype | ||||||||||||||
| B-other | 53 | 1.0* | NA | 82 | 1.0* | NA | ||||||||
| BCR-ABL | 4 | 2.32 | 0.51-10.6 | .28 | 9 | 9.09 | 2.48-33.3 | < .001 | ||||||
| Hyperdiploid† | 40 | 0.15 | 0.03-0.65 | .01 | 50 | 0.84 | 0.28-2.45 | .74 | ||||||
| MLL rearranged | 4 | 9.51 | 2.47-36.5 | .001 | 8 | 1.97 | 0.37-10.3 | .42 | ||||||
| TEL-AML1 | 44 | 0.18 | 0.05-0.68 | .01 | 70 | 0.93 | 0.18-4.73 | .93 | ||||||
| T-lineage | 35 | 0.79 | 0.33-1.93 | .6 | 38 | 2.73 | 1.11-6.71 | .029 | ||||||
| OPAL1 expression | 180 | 1.03 | 0.77-1.34 | .9 | 257 | 0.71 | 0.4-1.28 | .25 | ||||||
Cox multivariate proportional hazards analysis computed with known prognostic factors (ie, age, WBC count, immunophenotype, and genetic subtype). OPAL1 expression was treated as a continuous variable.
95% CI indicates 95% confidence interval; NA, not applicable.
Reference group.
Cytogenetic analysis revealed more than 50 chromosomes.